Kevin A. Sabet

Ismail Ali, Director of Policy and Advocacy at MAPS, passionately supports psychedelics as promising mental health treatments, particularly for those unresponsive to conventional therapies. In contrast, Kevin Sabet, former White House drug policy advisor, raises alarms about the unknown long-term effects of these substances. They dive into the ethical concerns of legalization, the need for rigorous regulation, and the ongoing debate surrounding the legitimacy of psychedelic research. Tune in for a thought-provoking clash on mental health and psychedelics!

Join Matthew Johnson, a celebrated psychiatry professor at Johns Hopkins, Shayla Love, a keen freelance science reporter, and Kevin Sabet, a drug policy expert, as they dive into the psychedelic renaissance. They explore whether substances like LSD and psilocybin can truly revolutionize mental health treatment. The discussion highlights the importance of subjective experiences over mere biochemistry, the risks of commercialization, and systemic inequities in mental health care access. Can psychedelics fulfill their promise, or is the hype too great?

Peter Grinspoon, a physician and cannabis specialist, and Kevin Sabet, a drug policy advisor, engage in a lively debate about the consequences of legalized cannabis. They discuss the significant increase in public support for marijuana, alongside health risks such as heart attacks and psychosis, particularly among young users. The conversation addresses the complexities of commercialization, regulation, and the historical context of cannabis use, raising questions about personal freedom versus public health and the future of cannabis legislation in the U.S.